DDInter575 DDInter1294
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Disopyramide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Disopyramide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Disopyramide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Disopyramide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Nilutamide
Disopyramide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Nilutamide
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nilutamide
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Disopyramide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Disopyramide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Nilutamide (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Disopyramide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Nilutamide (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with POR (Gene) and POR (Gene) is bound by Nilutamide (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Nilutamide (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Nilutamide (Compound)